SFDA Calls For Re-evaluation Of High-Risk Drugs
This article was originally published in PharmAsia News
Executive Summary
China's State FDA will undertake a number of measures to strengthen supervision of drugs to enhance drug safety, including re-evaluating high-risk drugs, SFDA Deputy Director-General Wu Zhen announced in a national working-level meeting on drug safety and supervision. The re-evaluation process will start with injectable drugs. In addition, SFDA will also amend the "Statute Governing the Quality Management of Drug Manufacturing" to ensure risk management procedures are instituted. (Click here for more